NCT04537156View on ClinicalTrials.gov

Efficacy, Immunogenicity and Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

9,327

Participants

Timeline

Start Date

September 5, 2020

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Cervical Intraepithelial NeoplasiaCervical CancerCondylomata Acuminata
Interventions
BIOLOGICAL

Nonavalent HPV vaccine

Nonavalent HPV vaccine (270μg/0.5ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule.

BIOLOGICAL

Bivalent HPV vaccine

Bivalent HPV vaccine (60μg/0.5ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule.

Trial Locations (2)

210009

Jiangsu Provincial Centre for Disease Control and Prevention, Nanjing

610041

Sichuan Provincial Centre for Disease Control and Prevention, Chengdu

All Listed Sponsors
collaborator

Xiamen Innovax Biotech Co., Ltd

INDUSTRY

collaborator

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

INDUSTRY

lead

Xiamen University

OTHER